Information on total number of voting rights and shares composing the share capital as at February 28th, 2019
01 Março 2019 - 2:00PM
Information on total number of voting rights and shares composing
the share capital as at February 28th, 2019
Paris, March 1st, 2019 – 6.00PM CET -
Pixium Vision (FR0011950641 - PIX), a bioelectronic company
developing innovative bionic vision systems to allow patients who
have lost their sight to lead more independent lives, announces the
evolution of its share capital. The number of voting rights and
shares composing its share capital as at February 28th, 2019 is as
follow:
Total voting rights |
Total number of shares composing capital |
Total real voting rights (1):
21,958,908 |
22,006,363 (3) |
Total theoretical voting rights (2):
22,006,363 |
(1): The actual (or net) voting rights
correspond to the total number of voting rights exercisable at
General Meetings. They are calculated based on the total number of
voting rights attached to the total number of shares, less any
shares without voting rights (treasury shares, etc.).
(2): Theoretical (or gross) voting rights
include all voting rights attached to the shares (including those
without voting rights).
(3): Including 400,000 new shares in accordance
with the contract of Equity Line financing concluded with Kepler
Cheuvreux on December 21, 2018
Contacts
Pixium Vision Didier Laurens,
CFOinvestors@pixium-vision.com+33 1 76 21 47 68 |
Media
RelationsNewcap MediaAnnie-Florence Loyer -
afloyer@newcap.fr +33 1 44 71 00 12 / +33 6 88 20 35 59Léa Jacquin
- ljacquin@newcap.fr +33 1 44 71 94 94 |
US Investor RelationsICRDavid
Clairdavid.clair@icrinc.com+1 646 277 12 66 |
ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of
bionic vision for those who have lost their sight, enabling them to
regain partial visual perception and greater autonomy. Pixium
Vision’s bionic vision systems are associated with a surgical
intervention and a rehabilitation period. Pixium Vision is in
clinical stage with PRIMA, its sub-retinal miniature photovoltaic
wireless implant system, designed for patients who have lost their
sight due to outer retinal degeneration, initially for atrophic dry
age-related macular degeneration (dry AMD). Pixium Vision
collaborates closely with academic and research partners spanning
across the prestigious Vision research institutions including
Stanford University in California, Institut de la Vision in Paris,
Moorfields Eye Hospital in London, and Institute of Ocular
Microsurgery (IMO) in Barcelona. The company is EN ISO 13485
certified and qualifies as “Entreprise Innovante” by Bpifrance.
For more information, please visit: www.pixium-vision.com;
And follow us on: @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Disclaimer:
This press release may expressly or implicitly
contain forward-looking statements relating to Pixium Vision and
its activity. Such statements are related to known or unknown
risks, uncertainties and other factors that could lead actual
results, financial conditions, performance or achievements to
differ materially from Vision Pixium results, financial conditions,
performance or achievements expressed or implied by such forward
looking statements.
Pixium Vision provides this press release as of
the aforementioned date and does not commit to update forward
looking statements contained herein, whether as a result of new
information, future events or otherwise.For a description of risks
and uncertainties which could lead to discrepancies between actual
results, financial condition, performance or achievements and those
contained in the forward-looking statements, please refer to
Chapter 4 "Risk Factors" of the company’s Registration Document
filed with the AMF under number R16-033 on April 28, 2016 which can
be found on the websites of the AMF - AMF (www.amf-france.org) and
of Pixium Vision (www.pixium-vision.com).
IRIS® is trademark of Pixium-Vision SA
- Pixium_Vision- Evolution of shares capital - February 2019